Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Portfolio Pulse from
Amarin's VASCEPA®/VAZKEPA® (Icosapent Ethyl) shows significant cardiovascular benefits in a new study published in the Journal of the American Heart Association. The study indicates a 34% reduction in cardiovascular events, regardless of baseline LDL-C levels.
February 27, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's VASCEPA®/VAZKEPA® demonstrates a 34% reduction in cardiovascular events in a new study, potentially boosting the drug's market appeal and Amarin's stock.
The publication of a peer-reviewed study showing significant cardiovascular benefits of Amarin's drug could enhance its marketability and lead to increased sales, positively impacting Amarin's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100